{
    "nctId": "NCT04871516",
    "briefTitle": "Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer",
    "officialTitle": "A Single Center Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 55,
    "primaryOutcomeMeasure": "Change in wound status from baseline every 3-6 months after WBI to access incidence of grade 3 or more wound complications after breast conserving surgery.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer patients with biopsy proven invasive cancer\n* Clinically and radiographically node negative\n* No indication of metastatic disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Synchronous bilateral invasive cancer allowed\n* Negative serum pregnancy test within one month from the radiation therapy (RT) boost delivery\n* Willingness to participate in the clinical trial and adhere to the study protocol\n* Individuals of all races, genders and ethnic groups are eligible for this trial\n\nExclusion Criteria:\n\n* Need for neoadjuvant chemotherapy\n* Inflammatory breast cancer (cT4)\n* Multicentric tumor\n* Prior ipsilateral breast or thoracic RT\n* Contraindication for baseline magnetic resonance imaging (MRI)\n* Contraindication for surgery\n* Distant metastatic disease\n* Other synchronous cancer (besides bilateral breast)\n* Contraindication to radiation therapy (presence of scleroderma or other collagen vascular disease)\n* Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}